Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: October 15, 2009
Last updated: June 16, 2011
Last verified: June 2011

Carry out the cost-effectiveness analysis of rosiglitazone on a population in line with the rosiglitazone license and using UK costs

Condition Intervention
Diabetes Mellitus, Type 2
Drug: Rosiglitazone

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Cost-effectiveness of rosiglitazone [ Time Frame: From literature ] [ Designated as safety issue: No ]

Enrollment: 7641
Study Start Date: October 2008
Study Completion Date: February 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
All patients Drug: Rosiglitazone


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Adults - obtainable from the literature


Inclusion Criteria:

  • Rosiglitazone Type II Diabetes studies

Exclusion Criteria:

  • Studies without the required outcome
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00995995

Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT00995995     History of Changes
Other Study ID Numbers: 113030
Study First Received: October 15, 2009
Last Updated: June 16, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 08, 2015